After a drug has been approved, big ADRs are reported to MEDRA, but smaller side effects are not usually reported. While some may be known and in the drug label, novel side effects may occur in populations not included in the original trials. Small effects may lead to discontinuation or poor compliance.. Collecting better data about side effects and combining with genomic data could give improved pharmacogenomic prediction... more »

1. Divide "cancer" into multiple classes (ie breast, lung, pancreatic, etc.) and sequence tumors from 50-100 patients undergoing treatment. As with breast cancer, identify markers aligning with specific treatments and outcomes.
2. Perform the "clinical" trial. Use the deep sequencing as a diagnostic to aid in planning the treatment for a set of 50-100 patients for a given type of cancer. Track the outcomes: survival time,... more »